A 2-year-old girl from Mumbai with a history of failure to thrive and developmental delay presents with acute onset of irritability, poor feeding, and lethargy. Serum ammonia is 240 µmol/L. Plasma amino acid profile shows markedly elevated lysine, arginine, and ornithine with low citrulline and argininosuccinate. Urine shows elevated lysine, ornithine, and cystine. What is the most appropriate immediate next step?

Explanation

## Lysinuric Protein Intolerance (LPI) — Acute Hyperammonemia Management ### Clinical Recognition The amino acid profile is pathognomonic for **lysinuric protein intolerance (LPI)**: - Elevated plasma lysine, arginine, ornithine (cannot be reabsorbed in proximal tubule) - Elevated urinary lysine, ornithine, cystine (triple aminoaciduria) - Low citrulline and argininosuccinate (secondary to arginine deficiency in urea cycle) **Key Point:** LPI is caused by a defect in the cationic amino acid transporter (y+LAT1), leading to: 1. Loss of lysine, arginine, ornithine in urine 2. Deficiency of arginine (a urea cycle substrate) → impaired ammonia detoxification 3. Secondary hyperammonemia despite a structurally intact urea cycle ### Why This Patient Needs Benzoate/Phenylbutyrate (NOT IV Arginine) Unlike OTC deficiency, where the urea cycle enzyme is blocked: - In LPI, the urea cycle is **structurally intact** but starved of arginine substrate - IV arginine will be rapidly lost in urine (due to the transporter defect) and does NOT solve the problem - **Benzoate and phenylbutyrate activate alternative nitrogen-scavenging pathways** that bypass the urea cycle: - Benzoate → hippurate (removes 1 N per glycine conjugate) - Phenylbutyrate → phenylacetylglutamine (removes 2 N per glutamine conjugate) - These are the **definitive therapy** for LPI hyperammonemia ### Management Algorithm ```mermaid flowchart TD A["Hyperammonemia + Elevated Lys/Arg/Orn + Low Cit/ASUC"]:::outcome --> B{"Urine shows triple aminoaciduria?"}:::decision B -->|Yes| C["Suspect LPI"]:::outcome C --> D["Start benzoate + phenylbutyrate"]:::action D --> E["Protein restriction"]:::action E --> F["Monitor ammonia & amino acids"]:::action B -->|No| G["Consider OTC/other urea cycle defect"]:::outcome G --> H["IV arginine + protein restriction"]:::action ``` ### Protein Restriction Rationale - Reduces nitrogen load and ammonia generation - Essential in both LPI and urea cycle defects - Protein intake adjusted based on ammonia levels and growth needs **High-Yield:** The key discriminator between LPI and OTC deficiency: | Feature | OTC Deficiency | LPI | |---------|---|---| | Urine orotic acid | Markedly elevated | Normal | | Urine amino acids | Normal | Triple aminoaciduria (Lys, Orn, Cys) | | Plasma arginine | Normal or high | Low | | Plasma citrulline | Low | Low | | First-line therapy | IV arginine | Benzoate + phenylbutyrate | **Clinical Pearl:** LPI is autosomal recessive and common in Finnish and Japanese populations. Patients often present with recurrent hyperammonemia triggered by infections or high protein intake. ### Why IV Arginine Fails in LPI - Arginine is a cationic amino acid — it cannot be reabsorbed by the defective transporter - Exogenous IV arginine is rapidly filtered and lost in urine - Does not restore intracellular arginine pools needed for urea cycle function - Benzoate/phenylbutyrate work because they activate ammonia scavenging independent of arginine availability [cite:Harrison 21e Ch 355; Robbins 10e Ch 7]